Targeting Cancer. Transforming Therapies.
Seagen is where revolutionary science meets transformative cancer therapy.
Seagen is committed to advancing late-stage clinical trials and expanding the development of its portfolio both in and outside the U.S. to better the health of people with cancer. We are dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells.
We are focused on discovering, developing and commercializing a new generation of transformative cancer medicines and empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer.
Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients. ADCs are an integral part of the evolving cancer treatment paradigm with their specificity, stability and potency.
We are expanding indications for three already approved cancer medicines and a pipeline of more than five novel targeted therapies at various stages of preclinical and clinical testing designed to address significant unmet medical needs.
Seagen is where revolutionary science meets transformative cancer therapy.
Seagen is committed to advancing late-stage clinical trials and expanding the development of its portfolio both in and outside the U.S. to better the health of people with cancer. We are dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells.
We are focused on discovering, developing and commercializing a new generation of transformative cancer medicines and empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer.
Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients. ADCs are an integral part of the evolving cancer treatment paradigm with their specificity, stability and potency.
We are expanding indications for three already approved cancer medicines and a pipeline of more than five novel targeted therapies at various stages of preclinical and clinical testing designed to address significant unmet medical needs.
Location: United States, Washington, Bothell
Employees: 1001-5000
Founded date: 1998
Investors 1
| Date | Name | Website |
| 07.07.2021 | Internatio... | ibtplc.com |
Mentions in press and media 27
| Date | Title | Description |
| 16.07.2026 | When Biological Indicators Don’t Fit: Rethinking Sterility Testing in Oncology Manufacturing | Share Share Share Share Email Pfizer validation engineer, peer-reviewed author, and ASTM Committee E55.06 voting member Prasantha Pujari on solving qualification challenges where biologics meet cytotoxic drugs — and why the frameworks he bu... |
| 06.07.2026 | HSBC Drops Pfizer to Hold: Seagen ADC Miss Leaves $43B Bet Without Catalyst | By Adrian Parham Published: Jul 06 2026, 11:58 AM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 09.01.2026 | Real Chemistry Establishes RC Resolve, an Advisory Practice for Healthcare’s Most Critical Business, Regulatory and Value Inflection Points | Real Chemistry today announced the launch of RC Resolve, a healthcare advisory practice designed to help leaders navigate the value inflection points where science, business, economics, policy and risk management intersect. RC Resolve offer... |
| 16.12.2025 | Pfizer’s modest 2026 outlook shows its big investments will take time to pay off | Pfizer forecast modest 2026 guidance as it looks to counter waning Covid product sales and declines from older drugs with longer-term investments in its pipeline. The company expects adjusted profit of $2.80 to $3 per share next year, and r... |
| 08.11.2025 | Accipiter Biosciences Secures $12.7M Seed Funding, Revolutionizing Protein Therapies | Accipiter Biosciences, a Seattle biotech, exited stealth with $12.7 million in seed funding. The company pioneers de novo multifunctional protein therapeutics. Its computational platform designs novel biologics from scratch. These single mo... |
| 07.11.2025 | Accipiter Biosciences: $12.7 Million Seed Funding Closed To Develop De Novo Protein Therapies | Accipiter Biosciences has emerged from stealth with $12.7 million in seed funding to advance a new class of de novo multifunctional protein therapeutics designed to treat complex diseases. The seed round was co-led by Takeda and Flying Fish... |
| 04.11.2025 | Pfizer tops estimates, raises profit guidance even as sales fall | Pfizer reported third-quarter earnings and revenue that topped estimates and hiked its full-year profit outlook as it cuts costs, even as sales for the period fell. The pharmaceutical giant now expects its full-year adjusted profit to come ... |
| 23.07.2025 | Cramer’s Lightning Round: Lowe’s is a buy | Monday - Friday, 6:00 - 7:00 PM ET It’s that time again! “Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at rapid speed. Pfizer: “We’re still on the verge of findin... |
| 06.06.2025 | JPMorgan’s top biotech and pharma picks for the second half | - |
| 20.12.2024 | Ottimo Pharma: A New Dawn in Cancer Treatment with $140 Million Boost | In the world of biotechnology, every dollar counts. Ottimo Pharma, a New York City-based biotech firm, has just raised over $140 million in a Series A funding round. This infusion of capital is not just a financial milestone; it’s a beacon ... |
Show more